Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics appointed Kevin Norrett as Chief Business Officer, promoted Charles Carter to Chief Financial Officer, and elevated Victoria Fort to Chief Strategy Officer to support its next phase of development. The company also named Eliseo Salinas as Executive R&D Advisor, leveraging his experience with 15 regulatory approvals to support the KCC2 activator pipeline.
Key figures
- Cash runway
- into 2029
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.